Product analysis
SAMe 200 mg offers a compound involved in normal metabolism, with limited value for the serving cost.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality20
The SAMe form is not specified, limiting a confident quality comparison. The available information does not establish poor ingredient quality.
Ingredient Transparency63
The amount is disclosed, helping you compare servings. The form is omitted, so the preparation remains unclear.
Value For Money40
SAMe offers limited value for the amount supplied. The cost comparison does not establish a practical benefit from the serving.
Customer Satisfaction77
Customer feedback is positive across several hundred ratings. No specific customer experiences are described.
Product Focus72
The formula stays focused on SAMe and its role in normal metabolism. That role does not establish routine toxin clearance or a general detox benefit.
- Format
Tablet - Container
- 60 Tablet(s)
- Per serving
- $0.58
- Customer rating
- 4.6 · 651 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
SAMe | 200 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability77
Stabilized Salt Form
Packaging Integrity
Dose, Safety & Label Transparency88
Active Dosage Strength
Net SAMe Yield Transparency
Value40
Price Per 400mg Active Dose
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.